| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Premature Birth | 13 | 2023 | 380 | 3.430 |
Why?
|
| Adrenal Cortex Hormones | 12 | 2023 | 317 | 2.890 |
Why?
|
| Prenatal Care | 11 | 2023 | 343 | 1.950 |
Why?
|
| Glucocorticoids | 8 | 2024 | 378 | 1.790 |
Why?
|
| Pregnancy | 52 | 2024 | 7148 | 1.640 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 2 | 2022 | 79 | 1.520 |
Why?
|
| Fetal Membranes, Premature Rupture | 6 | 2013 | 60 | 1.210 |
Why?
|
| Pregnancy Complications | 7 | 2011 | 507 | 1.210 |
Why?
|
| Gestational Age | 12 | 2024 | 1136 | 1.190 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2024 | 226 | 1.080 |
Why?
|
| Pre-Eclampsia | 4 | 2020 | 223 | 1.080 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 622 | 1.060 |
Why?
|
| Amniotic Fluid | 5 | 2016 | 151 | 1.010 |
Why?
|
| Ultrasonography, Prenatal | 6 | 2013 | 906 | 0.990 |
Why?
|
| Obstetric Labor, Premature | 6 | 2011 | 85 | 0.950 |
Why?
|
| Fetal Viability | 1 | 2024 | 29 | 0.920 |
Why?
|
| Perinatal Care | 1 | 2024 | 68 | 0.880 |
Why?
|
| Antithrombin III | 2 | 2013 | 25 | 0.820 |
Why?
|
| Thrombin | 2 | 2013 | 60 | 0.800 |
Why?
|
| Peptide Hydrolases | 2 | 2013 | 141 | 0.760 |
Why?
|
| Progesterone | 3 | 2009 | 624 | 0.720 |
Why?
|
| Female | 53 | 2024 | 65500 | 0.650 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2024 | 485 | 0.640 |
Why?
|
| Decision Making | 2 | 2024 | 651 | 0.640 |
Why?
|
| Edema | 3 | 2013 | 135 | 0.630 |
Why?
|
| Dexamethasone | 6 | 2013 | 272 | 0.630 |
Why?
|
| Progestins | 2 | 2009 | 48 | 0.610 |
Why?
|
| Infant, Newborn | 11 | 2024 | 8108 | 0.570 |
Why?
|
| Fetal Organ Maturity | 4 | 2011 | 14 | 0.540 |
Why?
|
| Pulmonary Surfactant-Associated Protein B | 3 | 2004 | 6 | 0.530 |
Why?
|
| Humans | 61 | 2024 | 123171 | 0.520 |
Why?
|
| Diseases in Twins | 2 | 2005 | 94 | 0.480 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2016 | 158 | 0.470 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 110 | 0.470 |
Why?
|
| Breech Presentation | 2 | 2006 | 21 | 0.470 |
Why?
|
| Cultural Diversity | 1 | 2015 | 63 | 0.470 |
Why?
|
| Culturally Competent Care | 1 | 2015 | 45 | 0.460 |
Why?
|
| Cultural Competency | 1 | 2015 | 52 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 1068 | 0.440 |
Why?
|
| Cervix Uteri | 4 | 2013 | 71 | 0.440 |
Why?
|
| Breast Diseases | 2 | 2004 | 34 | 0.440 |
Why?
|
| Foot Diseases | 1 | 2013 | 24 | 0.420 |
Why?
|
| Turner Syndrome | 1 | 2013 | 47 | 0.410 |
Why?
|
| Pregnancy Outcome | 9 | 2008 | 598 | 0.400 |
Why?
|
| Cerclage, Cervical | 2 | 2009 | 11 | 0.400 |
Why?
|
| Delivery, Obstetric | 3 | 2018 | 254 | 0.400 |
Why?
|
| Pregnancy, High-Risk | 2 | 2009 | 46 | 0.390 |
Why?
|
| Betamethasone | 5 | 2011 | 13 | 0.390 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 428 | 0.370 |
Why?
|
| Cervical Ripening | 2 | 2008 | 7 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 865 | 0.360 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 594 | 0.330 |
Why?
|
| Uterine Cervical Incompetence | 2 | 2006 | 6 | 0.330 |
Why?
|
| Fetal Growth Retardation | 1 | 2011 | 222 | 0.320 |
Why?
|
| Placenta | 2 | 2016 | 493 | 0.320 |
Why?
|
| Proteinuria | 3 | 2020 | 110 | 0.310 |
Why?
|
| Labor Onset | 1 | 2008 | 4 | 0.300 |
Why?
|
| HELLP Syndrome | 1 | 2007 | 19 | 0.280 |
Why?
|
| Down Syndrome | 1 | 2010 | 195 | 0.280 |
Why?
|
| Adult | 18 | 2017 | 29062 | 0.280 |
Why?
|
| Heart Ventricles | 1 | 2011 | 759 | 0.260 |
Why?
|
| Vaginosis, Bacterial | 1 | 2006 | 19 | 0.260 |
Why?
|
| Trial of Labor | 1 | 2006 | 21 | 0.260 |
Why?
|
| Thanatophoric Dysplasia | 1 | 2005 | 6 | 0.260 |
Why?
|
| Pregnancy Reduction, Multifetal | 1 | 2005 | 21 | 0.250 |
Why?
|
| Twins, Dizygotic | 1 | 2005 | 41 | 0.250 |
Why?
|
| Time Factors | 7 | 2016 | 6217 | 0.250 |
Why?
|
| Airway Obstruction | 1 | 2007 | 164 | 0.250 |
Why?
|
| Estrogen Antagonists | 1 | 2005 | 103 | 0.240 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 104 | 0.240 |
Why?
|
| Transient Tachypnea of the Newborn | 1 | 2024 | 2 | 0.240 |
Why?
|
| Environmental Pollutants | 1 | 2005 | 68 | 0.230 |
Why?
|
| NF-kappa B | 1 | 2007 | 455 | 0.230 |
Why?
|
| Community Health Planning | 1 | 2003 | 10 | 0.230 |
Why?
|
| Maternal Exposure | 1 | 2005 | 148 | 0.220 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2020 | 77 | 0.220 |
Why?
|
| Mammaplasty | 1 | 2004 | 54 | 0.220 |
Why?
|
| Uterine Rupture | 1 | 2003 | 18 | 0.210 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2003 | 90 | 0.210 |
Why?
|
| Urogenital Abnormalities | 1 | 2005 | 168 | 0.210 |
Why?
|
| Hypoglycemia | 1 | 2024 | 191 | 0.200 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 398 | 0.200 |
Why?
|
| Hydrops Fetalis | 1 | 2002 | 75 | 0.200 |
Why?
|
| Biomarkers | 4 | 2020 | 2946 | 0.200 |
Why?
|
| Cesarean Section | 2 | 2018 | 382 | 0.200 |
Why?
|
| Diabetes, Gestational | 1 | 2003 | 109 | 0.190 |
Why?
|
| Risk Factors | 6 | 2016 | 10010 | 0.190 |
Why?
|
| Cocaine | 1 | 2003 | 206 | 0.190 |
Why?
|
| Suture Techniques | 1 | 2003 | 198 | 0.190 |
Why?
|
| Tocolytic Agents | 2 | 2011 | 12 | 0.190 |
Why?
|
| Cocaine-Related Disorders | 1 | 2003 | 202 | 0.180 |
Why?
|
| Pregnancy, Multiple | 1 | 2000 | 50 | 0.170 |
Why?
|
| Maternal Age | 2 | 2011 | 137 | 0.170 |
Why?
|
| Eclampsia | 1 | 2020 | 32 | 0.170 |
Why?
|
| Embryo Transfer | 1 | 2000 | 82 | 0.170 |
Why?
|
| Nitric Oxide | 2 | 2016 | 439 | 0.170 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 964 | 0.170 |
Why?
|
| Cholecystectomy | 1 | 2019 | 56 | 0.160 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 1806 | 0.160 |
Why?
|
| Fetal Diseases | 1 | 2003 | 440 | 0.160 |
Why?
|
| Fertilization in Vitro | 1 | 2000 | 188 | 0.160 |
Why?
|
| Meningocele | 1 | 2018 | 20 | 0.150 |
Why?
|
| Mass Screening | 2 | 2020 | 788 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2003 | 607 | 0.150 |
Why?
|
| Lung | 5 | 2011 | 1475 | 0.140 |
Why?
|
| Parents | 1 | 2024 | 1030 | 0.140 |
Why?
|
| Hypertension | 1 | 2005 | 1287 | 0.140 |
Why?
|
| Creatinine | 2 | 2008 | 380 | 0.140 |
Why?
|
| Postpartum Hemorrhage | 1 | 2017 | 91 | 0.130 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 122 | 0.130 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2016 | 94 | 0.130 |
Why?
|
| Infant, Premature | 1 | 2001 | 799 | 0.130 |
Why?
|
| Complement C4a | 1 | 2015 | 4 | 0.130 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2016 | 137 | 0.130 |
Why?
|
| Peptide Hormones | 1 | 2016 | 66 | 0.130 |
Why?
|
| Complement Factor B | 1 | 2015 | 11 | 0.130 |
Why?
|
| Complement C5a | 1 | 2015 | 23 | 0.130 |
Why?
|
| Peer Review | 1 | 2015 | 40 | 0.130 |
Why?
|
| Quality Control | 1 | 2015 | 119 | 0.130 |
Why?
|
| Meningomyelocele | 1 | 2018 | 231 | 0.120 |
Why?
|
| Brain | 2 | 2024 | 2961 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 1088 | 0.120 |
Why?
|
| Amniocentesis | 2 | 2012 | 76 | 0.120 |
Why?
|
| Infant Mortality | 1 | 2016 | 175 | 0.120 |
Why?
|
| Ultrasonography | 2 | 2009 | 940 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 730 | 0.120 |
Why?
|
| Signal Transduction | 1 | 2007 | 4489 | 0.120 |
Why?
|
| Publishing | 1 | 2015 | 108 | 0.120 |
Why?
|
| Enzyme Activation | 2 | 2013 | 617 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2013 | 20 | 0.110 |
Why?
|
| Hypoxia, Brain | 1 | 2013 | 34 | 0.110 |
Why?
|
| Caspase 3 | 1 | 2013 | 131 | 0.110 |
Why?
|
| Syndrome | 2 | 2007 | 1115 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1262 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2004 | 3013 | 0.100 |
Why?
|
| Pregnancy in Diabetics | 1 | 2011 | 24 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2018 | 1243 | 0.100 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 699 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2015 | 3249 | 0.090 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2019 | 108 | 0.090 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2009 | 4 | 0.090 |
Why?
|
| Chimerism | 1 | 2010 | 28 | 0.090 |
Why?
|
| Parity | 1 | 2010 | 80 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2011 | 221 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 712 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 360 | 0.080 |
Why?
|
| Rare Diseases | 1 | 2011 | 185 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 2838 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2004 | 3273 | 0.080 |
Why?
|
| Fetal Mortality | 1 | 2008 | 7 | 0.080 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2008 | 30 | 0.080 |
Why?
|
| Uremia | 1 | 2008 | 35 | 0.080 |
Why?
|
| Procollagen | 1 | 2008 | 9 | 0.080 |
Why?
|
| Glomerulonephritis | 1 | 2008 | 73 | 0.080 |
Why?
|
| Lupus Nephritis | 1 | 2008 | 44 | 0.070 |
Why?
|
| Prostaglandins | 1 | 2008 | 47 | 0.070 |
Why?
|
| Cleft Lip | 1 | 2010 | 124 | 0.070 |
Why?
|
| Cleft Palate | 1 | 2010 | 140 | 0.070 |
Why?
|
| Collagen Type I | 1 | 2008 | 110 | 0.070 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2008 | 58 | 0.070 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2008 | 80 | 0.070 |
Why?
|
| Oxytocin | 1 | 2008 | 70 | 0.070 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 2007 | 20 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2011 | 1118 | 0.070 |
Why?
|
| Diabetic Nephropathies | 1 | 2008 | 110 | 0.070 |
Why?
|
| Prenatal Diagnosis | 1 | 2011 | 588 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2010 | 751 | 0.070 |
Why?
|
| Transcription Factor RelA | 1 | 2007 | 53 | 0.070 |
Why?
|
| Version, Fetal | 1 | 2006 | 7 | 0.070 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 159 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2008 | 262 | 0.070 |
Why?
|
| Trachea | 1 | 2007 | 201 | 0.060 |
Why?
|
| Potassium Chloride | 1 | 2005 | 54 | 0.060 |
Why?
|
| Postpartum Period | 1 | 2007 | 213 | 0.060 |
Why?
|
| Twins, Monozygotic | 1 | 2005 | 117 | 0.060 |
Why?
|
| Cryptorchidism | 1 | 2005 | 37 | 0.060 |
Why?
|
| Injections | 1 | 2005 | 153 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2017 | 16021 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2007 | 809 | 0.060 |
Why?
|
| Fetus | 1 | 2008 | 573 | 0.060 |
Why?
|
| Peptides | 1 | 2008 | 794 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2011 | 12129 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2006 | 164 | 0.060 |
Why?
|
| Anemia | 1 | 2008 | 340 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2008 | 747 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2012 | 6033 | 0.060 |
Why?
|
| Emergencies | 1 | 2005 | 174 | 0.060 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2003 | 1 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2004 | 1584 | 0.060 |
Why?
|
| Hypospadias | 1 | 2005 | 81 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 1683 | 0.060 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 138 | 0.060 |
Why?
|
| Radiography | 1 | 2005 | 823 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 267 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 628 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2106 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2003 | 80 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 1061 | 0.050 |
Why?
|
| United States | 3 | 2017 | 10631 | 0.050 |
Why?
|
| Acute Disease | 1 | 2005 | 1094 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2006 | 478 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2016 | 3042 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2008 | 842 | 0.050 |
Why?
|
| Kidney | 1 | 2008 | 1337 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2004 | 2813 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 1292 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2001 | 117 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2003 | 233 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2003 | 232 | 0.040 |
Why?
|
| Infant | 1 | 2016 | 12348 | 0.040 |
Why?
|
| Adenocarcinoma | 2 | 2004 | 993 | 0.040 |
Why?
|
| Heart | 1 | 2005 | 723 | 0.040 |
Why?
|
| Pregnancy Rate | 1 | 2000 | 48 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2004 | 1870 | 0.040 |
Why?
|
| Critical Care | 1 | 2005 | 648 | 0.040 |
Why?
|
| Gene Expression | 1 | 2004 | 1566 | 0.040 |
Why?
|
| Incidence | 1 | 2006 | 3047 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2004 | 1582 | 0.040 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2018 | 79 | 0.040 |
Why?
|
| Meningitis | 1 | 2018 | 99 | 0.040 |
Why?
|
| Labor, Obstetric | 1 | 2018 | 96 | 0.040 |
Why?
|
| Obstetric Labor Complications | 1 | 2018 | 96 | 0.040 |
Why?
|
| United Kingdom | 1 | 2017 | 191 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 5047 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 284 | 0.030 |
Why?
|
| Walking | 1 | 2018 | 207 | 0.030 |
Why?
|
| Young Adult | 1 | 2010 | 8863 | 0.030 |
Why?
|
| Trophoblasts | 1 | 2016 | 112 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2016 | 220 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2017 | 375 | 0.030 |
Why?
|
| Neural Tube Defects | 1 | 2018 | 351 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 514 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2003 | 3316 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 94 | 0.030 |
Why?
|
| Adolescent | 1 | 2010 | 19103 | 0.020 |
Why?
|
| Vagina | 1 | 2013 | 202 | 0.020 |
Why?
|
| Chorionic Villi Sampling | 1 | 2011 | 45 | 0.020 |
Why?
|
| Animals | 2 | 2003 | 33749 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2013 | 356 | 0.020 |
Why?
|
| Pregnancy Trimester, First | 1 | 2011 | 111 | 0.020 |
Why?
|
| Male | 2 | 2007 | 60084 | 0.020 |
Why?
|
| Genetic Counseling | 1 | 2011 | 225 | 0.020 |
Why?
|
| Physician's Role | 1 | 2011 | 164 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 325 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 425 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 1388 | 0.020 |
Why?
|
| Insulin | 1 | 2011 | 1200 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 826 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2011 | 995 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1590 | 0.010 |
Why?
|
| Respiratory Mucosa | 1 | 2004 | 90 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 849 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2004 | 247 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 1168 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 25994 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2525 | 0.010 |
Why?
|